Deepak Acharya, MD
Internal Medicine · Birmingham, ALNPI 1508043605
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,812 of the $5,052 with a category attached, or 75.4%. 9 manufacturers reported payments, led by Edwards Lifesciences at 47.9% of the total. Reporting peaked in 2019 at $2,158 and has fallen 92.7% since, to $157 in 2025.
Across 74 payments — averaging $68.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abiomed$905
- Medtronic$628
- Abbott$284
- Shockwave Medical, Inc$277
- Terumo Medical Corporation$191
- plus $348 from 3 others
Across 33 payments — averaging $1240.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$41K
- Abiomed$50
What the payments were for
- Travel & lodging$1,24025%
- Food & beverage$3,81275%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 24 | $2,419 |
| Abiomed | 15 | $905 |
| Medtronic(2 entities) | 9 | $628 |
| Abbott | 6 | $284 |
| Shockwave Medical, Inc | 13 | $277 |
| Terumo Medical Corporation | 3 | $191 |
| Teleflex LLC | 1 | $145 |
| Penumbra, Inc. | 1 | $139 |
| Philips North America LLC | 2 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,052 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 26 | $789,876 |
| EntrestoSacubitril/Valsartan | 74 | $100,462 |
| EliquisApixaban | 54 | $64,666 |
| FarxigaDapagliflozin Propanediol | 52 | $61,674 |
| JardianceEmpagliflozin | 34 | $43,378 |
| Repatha SureclickEvolocumab | 18 | $21,611 |
| XareltoRivaroxaban | 13 | $20,224 |
| Repatha SyringeEvolocumab | 14 | $13,155 |
| BrilintaTicagrelor | 12 | $9,689 |
| Rosuvastatin Calcium | 112 | $2,060 |
| Atorvastatin Calcium | 131 | $1,598 |
| Eplerenone | 12 | $1,339 |
| Metoprolol Succinate | 80 | $1,253 |
| Carvedilol | 158 | $1,165 |
| Torsemide | 29 | $1,066 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Birmingham
- Ryan WeldonBirmingham$458K
- Robert LewisBirmingham$187K
- Thomas HuddleBirmingham$76K
- Jose VargasBirmingham$49K
- Donna FicoBirmingham$46K
- James SullivanBirmingham$39K
- Ross SchumacherBirmingham$26K
- Larry AlfordBirmingham$25K
- David WynneBirmingham$22K
- James CrenshawBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.